Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0360-3016(92)90542-PPMID 1374065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Methods for Survival Data Analysis

  1994cited by this paper
• Prostate‐Specific Antigen and External Beam Radiation Therapy in Prostate Cancer

  1991cited by this paper
• The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels.

  1990cited by this paper
• Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate.

  1990cited by this paper
• Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.

  1990cited by this paper
• Prostate specific antigen and local recurrence after radical prostatectomy.

  1990cited by this paper
• Prostate specific antigen after irradiation for prostatic carcinoma.

  1990cited by this paper
• Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases.

  1990cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.

  1989cited by this paper
• Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.

  1989cited by this paper
• Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.

  1989cited by this paper
• Clinical use of prostate specific antigen in patients with prostate cancer.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.

  1989cited by this paper
• Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

  1988cited by this paper
• Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

  1988cited by this paper
• The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate.

  1988cited by this paper
• Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

  1988cited by this paper
• Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation

  1987cited by this paper
• Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate

  1987cited by this paper
• Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.

  1985cited by this paper
• Histologic grading study of prostate adenocarcinoma: The development of a new system and comparison with other methods—A preliminary study

  1982cited by this paper
• A computer program for comparing K samples with right-censored data.

  1972cited by this paper
• STATISTICAL METHODS

  1967cited by this paper

• Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

  2020cites this paper
• The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression

  2020cites this paper
• Prognostic factors in prostate cancer patients treated by radical external beam radiotherapy.

  2017cites this paper
• Morphological aspects of recurrent prostate cancer : on molecular imaging for local salvage treatment

  2015cites this paper
• Long-term Survival in a Patient with Metastatic Spinal Cord Compression from a Prostate Cancer with Ultra-high PSA: Case Report and Review of the Literature

  2015cites this paper
• Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations

  2014cites this paper
• The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?

  2013influential citation
• High-risk prostate cancer: from definition to contemporary management.

  2012cites this paper
• Management of Biochemical Recurrence after Primary Localized Therapy for Prostate Cancer

  2012influential citation
• Prognostic factors in prostate cancer

  2006cites this paper
• Gene therapy strategies to enhance the effectiveness of cancer radiotherapy.

  2004cites this paper
• Gene therapy strategies to improve the effectiveness of cancer radiotherapy

  2004cites this paper
• Iodine-125 brachytherapy for prostate cancer: first published Australian experience.

  2004cites this paper
• Early prostate‐specific antigen (PSA) kinetics following prostate carcinoma radiotherapy

  2004cites this paper
• Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.

  2003cites this paper
• Transrectal Ultrasound-Guided Prostate Brachytherapy

  2003cites this paper
• Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.

  2002cites this paper
• [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].

  2002cites this paper
• Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.

  2002cites this paper
• Suivi biologique du cancer de la prostate traité par radiothérapie exclusive : valeur pronostique du PSA pré-thérapeutique, du PSA Nadir et de la demi-vie du PSA

  2002cites this paper
• An update on prostate cancer

  2001cites this paper
• Radiation Therapy Options in the Treatment of Prostate Cancer

  2000cites this paper
• Counseling the Patient on Choice of Therapy and Outcomes

  2000cites this paper
• Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.

  1999cites this paper
• Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation.

  1999cites this paper
• The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer

  1998cites this paper
• Prognostic value of prostate specific antigen before, during and after radiotherapy.

  1998cites this paper
• Factors that influence biochemical failure after radiation therapy for stage T1c prostate cancer.

  1998cites this paper
• Strategies for improving the outcome of patients with poor prognosis prostate cancers.

  1998cites this paper
• Traitement des cancers prostatiques A2-B2: résultats d'une association hormonoradiothérapique dans l'ère du PSA

  1998cites this paper
• [Treatment of A2-B2 prostatic cancer: results of a hormonoradiotherapy combination in the PSA era].

  1998cites this paper
• Kombinierte Brachytherapie und antiandrogene Therapie beim Prostatakarzinom

  1998cites this paper
• Watchful waiting or watchful progression?

  1998cites this paper
• Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer.

  1997cites this paper
• Interstitial implantation techniques in prostate cancer

  1997cites this paper
• Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.

  1997cites this paper
• Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation

  1997cites this paper
• Analyzing predictive models following definitive radiotherapy for prostate carcinoma

  1997cites this paper
• External beam radiotherapy dose response of prostate cancer.

  1997cites this paper
• Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.

  1997cites this paper
• Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.

  1997cites this paper
• Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

  1997cites this paper
• Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate.

  1997cites this paper
• Prognostic factors for clinically localized prostate carcinoma

  1997cites this paper
• Does brachytherapy have a role in the treatment of prostate cancer?

  1996cites this paper
• Patterns of care survey results: treatment planning for carcinoma of the prostate.

  1995cites this paper
• Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography

  1995cites this paper
• Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.

  1995cites this paper
• Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.

  1995cites this paper
• Intracavitary birdcage resonator: Applications to the human prostate

  1995cites this paper
• Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.

  1995cites this paper
• Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.

  1995cites this paper
• Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.

  1995cites this paper
• Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy.

  1995cites this paper
• Gleason grade and other prognostic factors--response to Drs. Hammond and Grignon.

  1995cites this paper
• Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate.

  1995cites this paper
• Are only low pretreatment PSA patients curable? Regarding Kuban et al., IJROBP 32:307-316; 1995.

  1995cites this paper
• Primary radiation therapy in the treatment of localized prostatic cancer.

  1995cites this paper
• Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.

  1995cites this paper
• Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate.

  1995cites this paper
• Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer.

  1995cites this paper
• Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.

  1995cites this paper
• The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?

  1995cites this paper
• Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report.

  1994cites this paper
• Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.

  1994cites this paper
• The prostate specific antigen. Its use as a tumor marker for prostate cancer.

  1994cites this paper
• [Radiotherapy of prostatic cancer].

  1994cites this paper
• The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

  1994cites this paper
• Proliferative cell nuclear antigen in postradiotherapy prostate biopsies.

  1994cites this paper
• Facteur pronostiques du cancer de la prostate. Revue de la littérature et perspectives d'avenir

  1994cites this paper
• Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study.

  1994cites this paper
• Short-term freedom from disease progression after I-125 prostate implantation.

  1994cites this paper
• Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.

  1994cites this paper
• Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.

  1994cites this paper
• Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.

  1994cites this paper
• The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment.

  1994cites this paper
• Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate.

  1993cites this paper
• Cancer of the prostate.

  1993cites this paper
• Refining the predictive power of the prostate-specific antigen.

  1993cites this paper
• Serum PSA as a tumor marker for patients undergoing definitive radiation therapy.

  1993cites this paper
• The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate.

  1993cites this paper
• Current Status of Prostate-Specific Antigen in the Radiotherapeutic Management of Prostatic Cancer.

  1993cites this paper
• The fall and rise of prostate‐specific antigen: Kinetics of serum prostate‐specific antigen levels after radiation therapy for prostate cancer

  1993cites this paper
• Short-term results of computerized tomographic-based transperineal iodine-125 prostate implantation

  1993cites this paper
• The impact of prostatic manipulation upon serum PSA in patients with adenocarcinoma of the prostate.

  1993cites this paper
• Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.

  1993cites this paper
• Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

  1993cites this paper
• PSA after definitive radiotherapy for clinically localized prostate cancer.

  1993cites this paper
• Definitive External Irradiation in Stages A (T1) and B (T2) Carcinoma of the Prostate

  1993cites this paper